Andy Batts
Long only, value, growth, momentum

BioSpecifics Technologies: Another Xiaflex Play With Upcoming Catalysts

BioSpecifics Technologies (NASDAQ:BSTC) is a commercial-stage biotech company engaged in the development and commercialization of injectable collagenase for a broad range of clinical indications. Currently injectable collagenase is marketed as Xiaflex for a condition known as Dupuytren's Contracture. BioSpecifics has tremendous opportunities in Xiaflex and the shares of the company have huge upside potential over the medium-term.

Company Overview

BioSpecifics is currently conducting Phase II clinical trials of Xiaflex for two indications, human lipoma and canine lipoma. BioSpecifics is not the only company developing Xiaflex. In fact, its strategic partner Auxilium (NASDAQ:AUXL) has been marketing Xiaflex for Dupuytren's Contracture and conducting clinical trials of Xiaflex for Peyronie's Disease, Frozen Shoulder (Adhesive Capsulitis) and Cellulite (Edematous Fibrosclerotic

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details